drugset
drugset / Trial / NCT06218888

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

NCT06218888 ↗

Phase 2 Not yet recruiting 17 enrolled Fujian Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

To explore the Efficacy and Safety of Tislelizumab combined with fruquintinib and Chidamide in the treatment of unresectable or advanced microsatellite stabilized (MSS/pMMR) colorectal cancer with liver metastases

Timeline

Start
2024-06-01
Primary completion
2025-12-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 3 mg Oral
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous
Subject Tucidinostat Small molecule 30 mg Oral

Indications

colorectal cancer